Trial Profile

Phase 2/3 study of S-217622 in SARS-CoV-2 infected subjects

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ensitrelvir (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Acronyms SCORPIO-SR
Sponsors Shionogi

Most Recent Events

01 Apr 2025 Results published in the Antiviral Research
01 Sep 2024 Results published in the Antiviral Research
05 Mar 2024 According to a Shionogi media release, based on the Phase 3 portion results from this trial, the company has obtained standard approval from the Ministry of Health, Labour and Welfare (MHLW) for Xocova (Generic name: ensitrelvir fumaric acid), a novel anti-SARS-CoV-2 drug for the indication of SARS-CoV-2 infection in Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com